Novo Nordisk’s next-gen weight loss drug and Zepbound “seem fairly equal to me,” one expert says after release of new ...

The combination of once-weekly cagrilintide 2.4 mg and semaglutide 2.4 mg conferred greater weight loss at 68 weeks compared with placebo in patients with overweight or obesity with or without ...

Novo Nordisk on Sunday said full results from two late-stage trials of its experimental weight-loss drug CagriSema show that side effects were mainly mild-to-moderate and other outcome results, ...

An obesity drug from China helped patients lose a lot of weight in a late-stage clinical trial, making it a prospective new ...

Overweight patients given an experimental weight loss drug being developed by China's Sciwind Biosciences lost an average of ...

There is new guidance on the use of popular weight loss medications like Zepbound and Wegovy to help improve heart health.

If you're looking to add growth to your portfolio, biotech stocks can be a great choice. As an investor in these companies, ...

Novo Nordisk A/S’s next-generation obesity shot CagriSema helped patients lose weight in large studies despite only about three-quarters of the patients ever making it to the highest dose.

Q: My doctor is suggesting that I try taking one of those new weight loss drugs -- off-label -- to help me cut down on my alcohol consumption. Does this make any sense? -- Pat R., Ann Arbor, Michigan ...

Expect social and relationships to change after weight loss. The more weight you lose and the more you change your lifestyle ...